Novo Nordisk Highlights the Part 1 Results from P-III (ESSENCE) Study of Semaglutide to Treat MASH at AASLD 2024 - The Liver Meeti...
Shots: The P-III (ESSENCE) study assessed semaglutide (2.4mg, QW) vs PBO in MASH a...
Eli Lilly Reports the Data from P-II Trial of Muvalaplin in Adults with High Risk for Cardiovascular Events
Shots: Eli Lilly's P-II clinical evaluation of muvalaplin (10mg, 60mg & 24...
EnteroBiotix Concludes Recruitment for P-II Trial of EBX-102-02 in IBS
Shots: EnteroBiotix reported the completion of recruitment in its P-II (TrIuMPH) t...
Johnson & Johnson to Feature Analysis from P-II (DAHLIAS) Study of Nipocalimab for Treating Sjögren’s Disease at ACR Convergence 2...
Shots: J&J to highlight 43 presentations incl. data from P-II (DAHLIAS) study...
